Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Tidewater Inc (TDW) Price & Performance

ADMA Biologics IncTrade
Tidewater IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Tidewater Inc — how do they compare? ADMA Biologics Inc trades at $9.96 (market cap $2.22B), while Tidewater Inc trades at $91 (market cap $4.54B). The key difference: Tidewater Inc is far larger — about 2× ADMA Biologics Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMATDW
Market Cap
$2.22B$4.54B
Sector
HealthUtilities
52-Week High
$20.38$91.20
52-Week Low
$7.60$47.29
Enterprise Value
$2.29B$4.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Tidewater Inc

Tidewater (TDW) trades at $90.20, up 0.64% today, with a bullish technical signal driven by moving averages and ADX. Recent Q2 2026 earnings beat estimates (EPS $0.43 vs. $0.32 expected, Zacks Investment Research, 2026-08-03), though quarterly EPS has missed expectations in three of the last four quarters. The company maintains strong profitability with an 18.34% net margin and robust cash flow from operations of $379.11 million in 2025.

Outlook is mixed: bullish technicals and institutional interest support upside, but earnings misses and a high RSI near overbought levels pose risks. Analyst consensus leans hold (57.7%), with valuation metrics like P/E of 18.5 suggesting fair pricing. Key risks include operational costs from Middle East conflicts and revenue volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Tidewater Inc

Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.

Read more on TDW